B-cell malignancies and COVID-19: a narrative review.

ABSTRACT:

Background

COVID-19 has been extensively characterized in immunocompetent hosts and to a lesser extent in immunocompromised populations. Among the latter, patients treated for B-cell malignancies have immunosuppression generated by B-cell lymphodepletion/aplasia resulting in a higher susceptibility to respiratory virus infections and poor response to vaccination. The consequence is that these patients are likely to develop severe or critical COVID-19.

Objectives

To examine the overall impact of COVID-19 in patients treated for a B-cell malignancy or receiving chimeric antigen receptor T (CAR-T) immunotherapy administered in case of relapsed or refractory disease.

Sources

We searched in the Medline database to identify relevant studies, trials, reviews, or meta-analyse

SUBMITTER: Luque-Paz D 

PROVIDER: S-EPMC9633106 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature